
## Revolutionize Your PD-1 Research with RMP1-14-LALAPG

# The Next Generation of RMP1-14: Enhanced Efficacy, Lower Doses, Clearer Results

#### Tumor Growth Inhibition: Tumor Volume Over Time



#### Unleash the Power of LALAPG Technology

ICH1182LALAPG, our murinised LALAPG version of the gold-standard RMP1-14 antibody, demonstrates superior tumor growth inhibition compared to the traditional RMP1-14 (BE0146).

#### **Key Advantages:**


- 1. Enhanced Tumor Killing Effect: Statistically significant improvement in tumor growth inhibition (p < 0.05 on days 3, 5, and 14)
- 2. Potential for Lower Dosing: Achieve better results with less antibody
- 3. Improved Experimental Clarity: Set a new baseline for anti-PD-1 efficacy in your studies



### ichorbio

## Revolutionize Your PD-1 Research with RMP1-14-LALAPG

#### **Body Weight Change Over Time**



#### Maintain Research Integrity with Comparable Safety Profile

ICH1182LALAPG shows a similar impact on body weight as traditional RMP1-14, ensuring continuity in your experimental protocols.

#### Why Switch to ICH1182LALAPG?

- 1. Optimize Your Research: Achieve more pronounced effects with the same or lower doses
- 2. Enhance Sensitivity: Better differentiate the impact of your novel therapeutics from baseline anti-PD-1 effects
- 3. Streamline Experiments: Potential for shorter study durations or reduced animal numbers
- 4. Stay Cutting-Edge: Align your research with the latest advancements in antibody engineering



### ichorbio

### Revolutionize Your PD-1 Research with RMP1-14-LALAPG

#### Elevate Your Immuno-Oncology Studies

By incorporating ICH1182LALAPG into your research:

- Gain a clearer understanding of your experimental treatments'
  efficacy
- Potentially reduce time and resources needed for conclusive results
- Set a new gold standard for anti-PD-1 controls in your lab

#### **Expert Opinion**

"ICH1182LALAPG represents a significant leap forward in anti-PD-1 antibodies for preclinical research. Its enhanced tumor growth inhibition properties offer researchers a more powerful tool to evaluate novel cancer therapies." - Dr. Elaine Zhang, Lead Researcher

#### **Ready to Upgrade Your Research?**

Contact us today to learn how ICH1182LALAPG can transform your immuno-oncology studies.

More information: <a href="mailto:stratech.co.uk/ichorbio/revolutionize-your-pd-1-research-with-rmp1-14-lalapg/">stratech.co.uk/ichorbio/revolutionize-your-pd-1-research-with-rmp1-14-lalapg/</a>





#### stratech.co.uk/ichorbio



#### www.stratech.co.uk

info@stratech.co.uk +44 (0) 1638 782600



X @stratech\_uk @stratech-scientific-ltd

@stratech.scientific



we offer a full ø product guarnatee



free delivery for all UK Universities

Ó

0

outstanding technical support